Metabolome in progression to Alzheimer's disease

Translational Psychiatry

Volumn 1, Issue , 2011, Pages

  Oresic M ^a   Hyotylainen T ^a   Herukka, S K ^b   Sysi Aho, M ^a   Mattila, I ^a   Seppanan Laakso T ^a   Julkunen, V ^b   Gopalacharyulu, P V ^a   Hallikainen, M ^b   Koikkalainen, J ^a   Kivipelto, M ^c   Helisalmi, S ^b   Lotjonen J ^a   Soininen, H ^b  

^a VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimer's disease; hypoxia; lipidomics; metabolomics; mild cognitive impairment, pentose phosphate pathway

Indexed keywords

BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MALE; METABOLISM; METABOLOME; MILD COGNITIVE IMPAIRMENT; PATHOLOGY; PENTOSE PHOSPHATE CYCLE; PHYSIOLOGY; PREDICTIVE VALUE;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METABOLOME; MILD COGNITIVE IMPAIRMENT; PENTOSE PHOSPHATE PATHWAY; PREDICTIVE VALUE OF TESTS;

EID: 83755180492     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2011.55     Document Type: Article

References (65)

1. Qiu C, De Ronchi D, Fratiglioni L. The epidemiology of the dementias: An update. Curr Opin Psychiatry 2007; 20: 380-385. (Pubitemid 46889665)
2. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183-194. (Pubitemid 39222988)
3. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1133-1142. (Pubitemid 32405707)
4. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K et al. Mild cognitive impairment. Lancet 2006; 367: 1262-1270.
5. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007; 13: 1359-1362. (Pubitemid 350073592)
6. O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T et al. A serum proteinbased algorithm for the detection of Alzheimer disease. Arch Neurol 2010; 67: 1077-1081.
7. Illig T, Gieger C, Zhai G, Romisch-Margl W, Wang-Sattler R, Prehn C et al. A genomewide perspective of genetic variation in human metabolism. Nat Genet 2010; 42: 137-141.
8. Lenz EM, Bright J, Wilson ID, Hughes A, Morrisson J, Lindberg H et al. Metabonomics, dietary influences and cultural differences: A 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. J Pharm Biomed Anal 2004; 36: 841-849. (Pubitemid 39469425)
9. Maeba R, Maeda T, Kinoshita M, Takao K, Takenaka H, Kusano J et al. Plasmalogens in human serum positively correlate with high-density lipoprotein and decrease with aging. J Atheroscler Thromb 2007; 14: 12-18.
10. Nikkilä J, Sysi-Aho M, Ermolov A, Seppänen-Laakso T, Simell O, Kaski S et al. Gender dependent progression of systemic metabolic states in early childhood. Mol Syst Biol 2008; 4: E197.
11. Oresic M, Simell S, Sysi-Aho M, Nä ntö-Salonen K, Seppänen-Laakso T, Parikka V et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med 2008; 205: 2975-2984.
12. Velagapudi VR, Hezaveh R, Reigstad CS, Gopalacharyulu PV, Yetukuri L, Islam S et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res 2010; 51: 1101-1112.
13. Oresic M. Metabolomics, a novel tool for studies of nutrition, metabolism and lipid dysfunction. Nutr Metab Cardiovasc Dis 2009; 19: 816-824.
14. van der Greef J, Stroobant P, Heijden Rvd. The role of analytical sciences in medical systems biology. Curr Opin Chem Biol 2004; 8: 559-565. (Pubitemid 39278355)
15. Hartmann T, Kuchenbecker J, Grimm MOW. Alzheimer's disease: The lipid connection. J Neurochem 2007; 103: 159-170.
16. Oresic M, Hänninen VA, Vidal-Puig A. Lipidomics: A new window to biomedical frontiers. Trends Biotechnol 2008; 26: 647-652.
17. Han X, Gross RW. Shotgun lipidomics: Electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev 2005; 24: 367-412. (Pubitemid 40665798)
18. Lagarde M, Geloen A, Record M, Vance D, Spener F. Lipidomics is emerging. Biochim Biophys Acta 2003; 1634: 61. (Pubitemid 37487709)
19. Kivipelto M, Helkala EL, Hänninen T, Laakso MP, Hallikainen M, Alhainen K et al. Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology 2001; 56: 1683-1689. (Pubitemid 32574567)
20. Hänninen T, Hallikainen M, Tuomainen S, Vanhanen M, Soininen H. Prevalence of mild cognitive impairment: A population-based study in elderly subjects. Acta Neurol Scand 2002; 106: 148-154.
21. Pennanen C, Kivipelto M, Tuomainen S, Hartikainen P, Hanninen T, Laakso MP et al. Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol Aging 2004; 25: 303-310. (Pubitemid 38220965)
22. Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273: 1274-1278.
23. Smith GE, Petersen RC, Parisi JE, Ivnik RJ, Kokmen E, Tangalos EG et al. Definition, course, and outcome of mild cognitive impairment. Aging Neuropsychol Cogn 1996; 3: 141-147. (Pubitemid 26355260)
24. Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull 1988; 24: 637-639.
25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn. American Psychiatric Association, 1994.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944. (Pubitemid 14076461)
27. Julkunen V, Niskanen E, Muehlboeck S, Pihlajamaki M, Kononen M, Hallikainen M et al. Cortical thickness analysis to detect progressive mild cognitive impairment: A reference to Alzheimer's disease. Dement Geriatr Cogn Disord 2009; 28: 404-412.
28. Tsukamoto K, Watanabe T, Matsushima T, Kinoshita M, Kato H, Hashimoto Y et al. Determination by PCR-RFLP of apo E genotype in a Japanese population. J Lab Clin Med 1993; 121: 598-602. (Pubitemid 23112654)
29. Nygren H, Seppanen-Laakso T, Castillo S, Hyotylainen T, Oresic M. Liquid Chromatography-Mass Spectrometry (LC-MS)-Based Lipidomics for Studies of Body Fluids and Tissues. Methods Mol Biol 2011; 708: 247-257.
30. Castillo S, Mattila I, Miettinen J, Oresic M, Hyö tyläinen T. Data analysis tool for comprehensive two-dimensional gas chromatography-time of flight mass spectrometry. Anal Chem 2011; 83: 3058-3067.
31. Pluskal T, Castillo S, Villar-Briones A, Oresic M. MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics 2010; 11: 395.
32. Kampstra P. Beanplot: A boxplot alternative for visual comparison of distributions. J Stat Soft 2008; 28(Code Snippet 1): 1-9.
33. Fraley C, Raftery AE. Model-based methods of classification: Using the mclust software in chemometrics. J Stat Soft 2007; 18: 1-13.
34. Dalgaard P. Introductory Statistics with R. Springer Verlag: New York, 2004.
35. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw 2010; 33: 1-22.
36. Yamashita T, Yamashita K, Kamimura R. A stepwise AIC method for variable selection in linear regression. Commun Stat Theory Methods 2007; 36: 2395-2403. (Pubitemid 47507509)
37. McCullogh P, Nelder JA. Generalized linear models. Chapman & Hall/CRC: New York, 1989.
38. Kankainen M, Gopalacharyulu P, Holm L, Oresic M. MPEA-Metabolite Pathway Enrichment Analysis. Bioinformatics 2011; 27: 1878-1879.
39. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Nat Acad Sci USA 2005; 102: 15545-15550. (Pubitemid 41528093)
40. Steuer R, Kurths J, Fiehn O, Weckwerth W. Observing and interpreting correlations in metabolomic networks. Bioinformatics 2003; 19: 1019-1026. (Pubitemid 36675824)
41. Brites P, Waterham HR, Wanders RJA. Functions and biosynthesis of plasmalogens in health and disease. Biochim Biophys Acta 2004; 1636: 219-231. (Pubitemid 38780799)
42. Farooqu AA, Horrocks LA. Plasmalogens, phospholipase A2, and docosahexaenoic acid turnover in brain tissue. J Mol Neurosci 2001; 16: 263-272; discussion 279-284. (Pubitemid 32664787)
43. Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW et al. Peripheral ethanolamine plasmalogen deficiency: A logical causative factor in Alzheimer's disease and dementia. J Lipid Res 2007; 48: 2485-2498. (Pubitemid 350058760)
44. Han X, Holtzman DM, McKeel Jr DW. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: Molecular characterization using electrospray ionization mass spectrometry. J Neurochem 2001; 77: 1168-1180. (Pubitemid 32467071)
45. Farooqui AA, Rapoport SI, Horrocks LA. Membrane phospholipid alterations in Alzheimer's disease: Deficiency of ethanolamine plasmalogens. Neurochem Res 1997; 22: 523-527. (Pubitemid 27184719)
46. He X, Huang Y, Li B, Gong CX, Schuchman EH. Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging 2010; 31: 398-408.
47. Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: The cholesterol connection. Nat Neurosci 2003; 6: 345-351. (Pubitemid 36373979)
48. Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR et al. Metabolomics in early Alzheimer's disease: Identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS ONE 2011; 6: E21643.
49. Laws SM, Hone E, Gandy S, Martins RN. Expanding the association between the APOE gene and the risk of Alzheimer's disease: Possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem 2003; 84: 1215-1236. (Pubitemid 36343589)
50. Bandaru VV, Troncoso J, Wheeler D, Pletnikova O, Wang J, Conant K et al. ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiol Aging 2009; 30: 591-599.
51. Nagan N, Zoeller RA. Plasmalogens: Biosynthesis and functions. Prog Lipid Res 2001; 40: 199-229. (Pubitemid 32220187)
52. Niemela PS, Hyvonen MT, Vattulainen I. Atom-scale molecular interactions in lipid raft mixtures. Biochim Biophys Acta 2009; 1788: 122-135.
53. Jang H, Arce FT, Ramachandran S, Capone R, Azimova R, Kagan BL et al. Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer's Disease and Down syndrome. Proc Natl Acad Sci USA 2010; 107: 6538-6543.
54. Oresic M, Lö tjönen J, Soininen H. Systems medicine and the integration of bioinformatic tools for diagnosis of Alzheimer's disease. Genome Med 2010; 2: E83.
55. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997; 23: 134-147. (Pubitemid 27217017)
56. Pratico D. Oxidative stress hypothesis in Alzheimer's disease: A reappraisal. Trends Pharmacol Sci 2008; 29: 609-615.
57. Alvarez XA, Franco A, Fernandez-Novoa L, Cacabelos R. Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease. Mol Chem Neuropathol 1996; 29: 237-252. (Pubitemid 27016932)
58. Cacabelos R, Fernandez-Novoa L, Perez-Trullen JM, Franco-Maside A, Alvarez XA. Serum histamine in Alzheimer's disease and multi-infarct dementia. Methods Find Exp Clin Pharmacol 1992; 14: 711-715. (Pubitemid 23057191)
59. 2+ influx. Biochem J 1998; 330(Part 2): 695-699.
60. Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 2003; 4: 121-130. (Pubitemid 37271382)
61. Hoffmann GF, Meier-Augenstein W, Stockler S, Surtees R, Rating D, Nyhan WL. Physiology and pathophysiology of organic acids in cerebrospinal fluid. J Inherit Metab Dis 1993; 16: 648-669. (Pubitemid 23237047)
62. Stoop MP, Coulier L, Rosenling T, Shi S, Smolinska AM, Buydens L et al. Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples. Mol Cell Proteomics 2010; 9: 2063-2075.
63. Niemelä K, Sjö ström E. Non-oxidative and oxidative degradation of D-galacturonic acid with alkali. Carbohydrate Res 1985; 144: 93-99.
64. Hakim AM, Moss G, Gollomp SM. The effect of hypoxia on the pentose phosphate pathway in brain. J Neurochem 1976; 26: 683-688.
65. Sun X, He G, Qing H, Zhou W, Dobie F, Cai F et al. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci USA 2006; 103: 18727-18732. (Pubitemid 44913478)